News

Press Release

Go to Topics

2021

Sysmex Obtains IVDR Certification for LYNOAMP™ CK19 E, a Gene Amplification Detection Reagent
- Prompt response to legislative changes in the European region that demand greater product safety - (PDF:184KB)
Th2 Chemokine TARC Kit "HISCL™ TARC Assay Kit" is Approved for an Additional Indication as an Auxiliary for Assessment of COVID-19 Aggravation risk (PDF:210KB)
Sysmex Relocates its PCR Testing Laboratory to its Research and Development Center for Expanded Functions (PDF:154KB)
Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2021
Sysmex Announces Changes from Financial Forecasts and Year-End Dividend for the Fiscal Year Ended March 31, 2021 (PDF:174KB)
Announcement of Executive Change (PDF:176KB)
Sysmex Announces New Group Mid-Term Management Plan
- Harnessing Groupwide Capabilities and Promoting Corporate Reforms with a View to Sustainable Growth - (PDF:210KB)
Sysmex and ThinkCyte Agree on Joint Development and Capital Alliance
- Commencing development of novel AI-based cell analyzers and testing techniques - (PDF:255KB)
Sysmex Obtains Manufacturing and Marketing Approval for Novel Coronavirus Detection Reagent (RT-PCR Method)
- Building a Self-Sufficient Production System in Japan for a Stable Supply of PCR Testing Kits - (PDF:169KB)
Sysmex Continues to Evolve Its Hematology Product Portfolio
- Flagship Model XR-Series and Compact 3-part WBC Differential Model XQ-Series to Be Rolled Out Sequentially - (PDF:209KB)
Announcement of Organizational and Personnel Changes (PDF:385KB)
Sysmex Presents Academic Report on Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood
- Presenting the Most Recent Data at the 15th International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD 2021) - (PDF:118KB)
Sysmex Obtains Manufacturing and Marketing Approval for an Influenza A/B Virus Antigen Detection Test Kit
Influenza can be simultaneously measured in a short period of time in the same the novel coronavirus (SARS-CoV-2) antigen sample using the HISCL™-5000/HISCL-800 Automated Immunoassay Systems - h (PDF:170KB)
Sysmex Receives Approval for a Partial Change to the OncoGuide™ NCC Oncopanel System for Use in Cancer Genome Profiling
- Detection of 10 New Gene Mutations Including MSH6 and PMS2, NTRK3 Gene Fusion and Microsatellite Instability - (PDF:238KB)
Insurance Coverage Received for HISCL™ IFN-λ3 Assay Kit, a Test Kit to Assist in Determining Exacerbation Risk in SARS-CoV-2-Positive Patients (PDF:192KB)
Summary of Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2021 (PDF:452KB)
Sysmex and Siemens Healthineers Extend Long-standing Global Alliance in Hemostasis Testing (PDF:148KB)
Sysmex Establishes New Subsidiary in Portugal
- Increasing Portuguese Market Presence by Enhancing Sales and After-Sales Support Networks - (PDF:163KB)
Sysmex and Yamato Logistics to Commence GDP-Compliant Transport of Reagents for Gene Testing at the Ultralow Temperature Range of Minus 70 Degrees Celsius or Below
- Also Commencing Experiments for Ultralow Temperature Transport Without Using Dry Ice - (PDF:251KB)
Sysmex Selected as One of the Global 100's Most Sustainable Companies in the World for the Fourth Time (PDF:173KB)
Sysmex and Roche Renew Agreement for Global Alliance
- Transforming a long-standing alliance into one for the next generation - (PDF:145KB)